Indication assessment · §3
Heart failure with preserved ejection fraction and obesity — trial records
Trial records in the Institute's register bearing on heart failure with preserved ejection fraction and obesity.
§3Trials in this indication
16 trial records in the Institute's register bear on this indication, of which 4 are published trials.
Table 2. Trial records bearing on heart failure with preserved ejection fraction and obesity.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| STEP-HFpEF | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 529 | 2023 |
| STEP-HFpEF-DM | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 616 | 2024 |
| SUMMIT | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | 731 | 2024 |
| ELAM-PH2-HFPEF | SS-31 (elamipretide) | Phase 2 | Randomised, double-blind, placebo-controlled | 71 | 2019 |
| STEP-HFpEF-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Phase 1 ascending dose | — | 2023 |
| STEP-HFpEF-DM-BODY-COMPprogramme record | Semaglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2024 |
| SUMMIT-BIOMARKERprogramme record | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2024 |
| ELAM-PH2-HFPEF-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 2 | Observational | — | 2019 |
| STEP-HFpEF-DDIprogramme record | Semaglutide | Phase 1 | Randomised crossover | — | 2023 |
| SUMMIT-ADHERENCEprogramme record | Tirzepatide | Phase 3 | Observational | — | 2024 |
| ELAM-PH2-HFPEF-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2019 |
| SUMMIT-OLEprogramme record | Tirzepatide | Phase 3 | Single-arm open-label | — | 2024 |
| ELAM-PH2-HFPEF-ELDERLYprogramme record | SS-31 (elamipretide) | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2019 |
| SUMMIT-ELDERLYprogramme record | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2024 |
| ELAM-PH2-HFPEF-OLEprogramme record | SS-31 (elamipretide) | Phase 2 | Single-arm open-label | — | 2019 |
| SUMMIT-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2024 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-06/3 · https://compoundevidence.com/indications/hfpef/trials/ · retrieved 30 July 2026